Generic placeholder image

Current Medicinal Chemistry


ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Repurposing Cilostazol for Raynaud's Phenomenon

Author(s): Nehme El-Hachem, Manal M. Fardoun, Hasan Slika, Elias Baydoun and Ali H. Eid*

Volume 28 , Issue 12 , 2021

Published on: 03 September, 2020

Page: [2409 - 2417] Pages: 9

DOI: 10.2174/0929867327666200903114154

Price: $65


Raynaud's Phenomenon (RP) results from exaggerated cold-induced vasoconstriction. RP patients suffer from vasospastic attacks and compromised digital blood perfusion leading to a triple color change at the level the fingers. Severe RP may cause ulcers and threaten tissue viability. Many drugs have been used to alleviate the symptoms of RP. These include calcium-channel blockers, cGMP-specific phosphodiesterase type 5 inhibitors, prostacyclin analogs, and angiotensin receptor blockers. Despite their variety, these drugs do not treat RP but rather alleviate its symptoms. To date, no drug for RP has been yet approved by the U.S Food and Drugs Administration. Cilostazol is a selective inhibitor of phosphodiesterase-III, originally prescribed to treat intermittent claudication. Owing to its antiplatelet and vasodilating properties, cilostazol is being repurposed as a potential drug for RP. This review focuses on the different lines of action of cilostazol serving to enhance blood perfusion in RP patients.

Keywords: Cardiovascular disease, cilostazol, digital ischemia, drug repurposing, Raynaud's phenomenon, Cold-induced vasoconstriction.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy